CN115698270A - 一种通过iPS细胞生产再生T细胞的方法 - Google Patents
一种通过iPS细胞生产再生T细胞的方法 Download PDFInfo
- Publication number
- CN115698270A CN115698270A CN202180038576.5A CN202180038576A CN115698270A CN 115698270 A CN115698270 A CN 115698270A CN 202180038576 A CN202180038576 A CN 202180038576A CN 115698270 A CN115698270 A CN 115698270A
- Authority
- CN
- China
- Prior art keywords
- cells
- ips
- cell
- immature
- hematopoietic stem
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4201—Neoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4242—Transcription factors, e.g. SOX or c-MYC
- A61K40/4243—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4261—Proteoglycans, e.g. glypican, brevican or CSPG4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/46—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18811—Sendai virus
- C12N2760/18841—Use of virus, viral particle or viral elements as a vector
- C12N2760/18843—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/90—Vectors containing a transposable element
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020-156848 | 2020-09-18 | ||
| JP2020156848 | 2020-09-18 | ||
| JP2021070531 | 2021-04-19 | ||
| JP2021-070531 | 2021-04-19 | ||
| PCT/JP2021/034333 WO2022059780A1 (ja) | 2020-09-18 | 2021-09-17 | iPS細胞を介する再生T細胞の製造方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115698270A true CN115698270A (zh) | 2023-02-03 |
Family
ID=80776150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180038576.5A Pending CN115698270A (zh) | 2020-09-18 | 2021-09-17 | 一种通过iPS细胞生产再生T细胞的方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230183645A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4215604A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JPWO2022059780A1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN115698270A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022059780A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3822342A4 (en) * | 2018-07-13 | 2022-08-03 | Kyoto University | METHOD OF PRODUCTION OF GAMMA DELTA T-CELLS |
| CA3213440A1 (en) * | 2021-04-16 | 2022-10-20 | Thyas Co. Ltd. | A cell bank composed of ips cells for transfecting t cell receptor gene |
| JPWO2023249071A1 (cg-RX-API-DMAC7.html) * | 2022-06-24 | 2023-12-28 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016010154A1 (ja) * | 2014-07-18 | 2016-01-21 | 宏 河本 | 抗原特異的t細胞受容体遺伝子を有する多能性幹細胞の製造方法 |
| CN105925535A (zh) * | 2009-06-05 | 2016-09-07 | 细胞动力国际有限公司 | 重编程t细胞和造血细胞的方法 |
| JP2018512380A (ja) * | 2015-03-13 | 2018-05-17 | サイズ セル セラピー コーポレイション | 活性化t細胞を用いるがん治療の方法 |
| GB201911953D0 (en) * | 2019-08-20 | 2019-10-02 | Adaptimmune Ltd | T cell production fram RAG inacivated iPSCs |
| CN111164204A (zh) * | 2017-10-06 | 2020-05-15 | 赛雅思株式会社 | 来自iPS细胞的具有遗传多样性的T细胞群体的制备方法 |
| CN112513256A (zh) * | 2018-07-13 | 2021-03-16 | 国立大学法人京都大学 | γδT细胞的制造方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2011096482A1 (ja) * | 2010-02-03 | 2013-06-13 | 国立大学法人 東京大学 | 多能性幹細胞を用いた免疫機能再建法 |
| JP5963309B2 (ja) * | 2010-11-09 | 2016-08-03 | 国立研究開発法人産業技術総合研究所 | 末梢血単球由来多能性幹細胞作製方法 |
| EP2853590B1 (en) * | 2012-05-22 | 2018-11-07 | The University of Tokyo | Method for producing antigen-specific t cells |
| AU2015290554A1 (en) * | 2014-07-18 | 2017-03-09 | Kyoto University | Method for inducing T cells for cell-based immunotherapy from pluripotent stem cells |
| US11603519B2 (en) * | 2017-02-06 | 2023-03-14 | National Cancer Center Japan | T-cell receptor |
| KR102946326B1 (ko) * | 2017-09-05 | 2026-03-31 | 시애틀 프로젝트 코포레이션 | T-세포 요법을 위한 신생항원 동정 |
| WO2020022512A1 (ja) * | 2018-07-26 | 2020-01-30 | 国立大学法人京都大学 | 外来抗原レセプター遺伝子導入細胞の製造方法 |
| WO2020027094A1 (ja) * | 2018-07-31 | 2020-02-06 | サイアス株式会社 | iPS細胞を介して再生T細胞集団を製造する方法 |
| US20210040558A1 (en) * | 2019-07-15 | 2021-02-11 | Neogene Therapeutics B.V. | Method to isolate tcr genes |
| BR112022009181A2 (pt) * | 2019-11-25 | 2022-07-26 | Univ Kyoto | Sistema para prover um produto de célula t, métodos para produzir um produto de célula t, para construir um banco celular e uma coleção de produto de célula t e para prover um produto de célula t, banco celular, coleções de banco celular e de produto de célula t, e, produto de célula t |
| EP4273234A4 (en) * | 2021-01-04 | 2025-04-23 | Thyas Co. Ltd. | Method for producing a regenerated T cell via an IPS cell |
| CA3213440A1 (en) * | 2021-04-16 | 2022-10-20 | Thyas Co. Ltd. | A cell bank composed of ips cells for transfecting t cell receptor gene |
-
2021
- 2021-09-17 JP JP2022550632A patent/JPWO2022059780A1/ja active Pending
- 2021-09-17 EP EP21869462.8A patent/EP4215604A4/en active Pending
- 2021-09-17 WO PCT/JP2021/034333 patent/WO2022059780A1/ja not_active Ceased
- 2021-09-17 US US17/924,480 patent/US20230183645A1/en active Pending
- 2021-09-17 CN CN202180038576.5A patent/CN115698270A/zh active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105925535A (zh) * | 2009-06-05 | 2016-09-07 | 细胞动力国际有限公司 | 重编程t细胞和造血细胞的方法 |
| WO2016010154A1 (ja) * | 2014-07-18 | 2016-01-21 | 宏 河本 | 抗原特異的t細胞受容体遺伝子を有する多能性幹細胞の製造方法 |
| JP2018512380A (ja) * | 2015-03-13 | 2018-05-17 | サイズ セル セラピー コーポレイション | 活性化t細胞を用いるがん治療の方法 |
| CN111164204A (zh) * | 2017-10-06 | 2020-05-15 | 赛雅思株式会社 | 来自iPS细胞的具有遗传多样性的T细胞群体的制备方法 |
| CN112513256A (zh) * | 2018-07-13 | 2021-03-16 | 国立大学法人京都大学 | γδT细胞的制造方法 |
| GB201911953D0 (en) * | 2019-08-20 | 2019-10-02 | Adaptimmune Ltd | T cell production fram RAG inacivated iPSCs |
Non-Patent Citations (2)
| Title |
|---|
| HARUKA WADA等: "Successful differentiation to T cells, but unsuccessful B-cell generation, from B-cell-derived induced pluripotent stem cells", INT IMMUNOL, 6 December 2010 (2010-12-06) * |
| 彭延文等: "体外诱导小鼠胚胎干细胞分化为T淋巴细胞", 中华生物医学工程杂志, 6 November 2008 (2008-11-06) * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4215604A1 (en) | 2023-07-26 |
| US20230183645A1 (en) | 2023-06-15 |
| WO2022059780A1 (ja) | 2022-03-24 |
| JPWO2022059780A1 (cg-RX-API-DMAC7.html) | 2022-03-24 |
| EP4215604A4 (en) | 2025-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7778708B2 (ja) | 多能性幹細胞からナチュラルキラー細胞を産生するための方法 | |
| JP5652783B2 (ja) | NKT細胞由来iPS細胞およびそれ由来のNKT細胞 | |
| US20220175899A1 (en) | Cytotoxic t lymphocytes specific for mutated forms of epidermal growth factor receptor for use in treating cancer | |
| US20210238550A1 (en) | METHOD FOR PRODUCING REGENERATED T CELL POPULATION VIA iPS CELLS | |
| US20170267972A1 (en) | Production method for pluripotent stem cells having antigen-specific t cell receptor gene | |
| CN108289909A (zh) | 用于产生工程改造的人原代血液树突细胞系的方法 | |
| EP4215604A1 (en) | Method for producing regenerated t cells via ips cells | |
| US20240052309A1 (en) | Method for producing regenerated t cell via ips cell | |
| US20250154458A1 (en) | Methods for Making, Compositions Comprising, and Methods of Using Rejuvenated T Cells | |
| US20200345789A1 (en) | Production method for ips cell-derived population of genetically diverse t cells | |
| EP4324917A1 (en) | Cell bank composed of ips cells for introducing t cell receptor gene | |
| JPWO2016010153A1 (ja) | 免疫細胞療法用t細胞の誘導方法 | |
| WO2022264033A1 (en) | Method for producing natural killer cells from pluripotent stem cells | |
| US20220233665A1 (en) | Medicinal composition | |
| CN116744947A (zh) | 一种通过iPS细胞生产再生T细胞的方法 | |
| CN116615209A (zh) | 制备再生t细胞的方法、包含再生t细胞的组合物及使用再生t细胞的方法 | |
| WO2025220666A1 (en) | Cytotoxic Lymphocytes Expressing Variable Region-Deleted T Cell Receptors | |
| WO2024071411A1 (ja) | iPS細胞から誘導された免疫細胞 | |
| WO2026103715A1 (zh) | 免疫细胞的筛选方法及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |